Furthermore, PD-L1 was predominantly expressed on tumor cells (CD45−) and myeloid cells (CD45+/CD11b+), though the specific impact of AXL targeting on these subsets requires further investigation. The gene discussed is PTPRC; the disease is neoplasm.